MPEP Mycobacterium Tuberculosis Drug Susceptibility Testing – Reports

The following information pertains to the tables and figures for each MPEP panel’s Final Report.

• First-line and second-line drugs have been separated into individual tables for each isolate. Streptomycin is classified as a second-line drug for this report.
• Separate tables for molecular testing are included.
• Laboratories that use more than one DST method are encouraged to test isolates with each of those methods at either CLSI-recommended or equivalent critical concentrations. Some laboratories have provided results for multiple DST methods. Consequently, the number of results for some drugs may be greater than the number of participating laboratories. This report contains all results reported by participating laboratories.
• The Trek Sensititre system allows determination of a minimum inhibitory concentration (MIC) for each drug in the panel. Laboratories using this method must establish breakpoints to provide a categorical interpretation of S or R.
• For participant result tables for first- and second-line DST that have drug-method totals equal to 0, results were not received or the test was not performed.

(Concentrations listed as µg/ml)

Agar Proportion

NOTE—Critical concentrations as indicated in CLSI M24 document [1]
*The higher concentration of INH should be tested as second-line drugs after resistance at the critical concentration is detected.
†CLSI critical concentrations for RMP differ from revised WHO recommendation of 0.5 µg/ml published in 2021 [2].

Broth Based Media

NOTE—Critical concentrations as indicated in applicable manufacturer package inserts
*The higher concentration of STR should be tested after resistance at the critical concentration is detected.
†Revised WHO recommendations provide LEV and MOX critical concentrations for MGIT published in 2018 [3].